The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE^−/− Mice

Figure 2

Changes of serum NLRP3 inflammasome, IL-1β, and IL-18 levels in mice from each group. (a), (b), and (c) represented the serum levels of NLRP3, IL-1β, and IL-18, respectively. After 12 weeks of treatment with dapagliflozin, the serum levels of NLRP3, IL-1β, and IL-18 significantly reduced in DM mice. ; .

(a)

(b)

(c)